Your Oncotype DX score tells you how likely your cancer is to return and whether chemotherapy would help. It's not the main factor in choosing between lumpectomy and mastectomy. These are separate decisions - and understanding the difference matters for how you plan your treatment.
What Is Oncotype DX?
Oncotype DX is a genomic test that looks at the genes in your cancer cells. It measures how active 21 genes are in a sample of your tumour tissue. The result is your Recurrence Score, a number from 0 to 100.
The test is for women with early-stage breast cancer that is hormone receptor-positive (oestrogen or progesterone receptor-positive), HER2-negative, and either node-negative or with up to three positive lymph nodes. If your cancer fits this profile, your team may recommend Oncotype DX to help figure out whether chemotherapy would reduce your risk of cancer spreading to other parts of your body.
According to Breast Cancer Now, the test is available on the NHS across the UK if you meet NICE criteria. Private cost is around £3,000. The tumour sample goes to a laboratory in the United States, and results usually come back in a few weeks.
Oncotype DX is not for everyone. If your cancer is already clearly high-risk by standard measures, your oncologist may recommend chemotherapy without this test. If your cancer is clearly low-risk, the test may not add new information. Your team will tell you whether it applies to you.
How the Recurrence Score Works
The lab measures how active the 21 genes are in your tumour sample. Some genes link to cancer growth. Others relate to how cancer responds to hormone therapy. Together, they produce one number - your Recurrence Score.
A higher score means a higher predicted risk of cancer returning in a distant part of your body - like the lungs, liver, or bones - and suggests chemotherapy may reduce that risk. A lower score suggests hormone therapy alone will likely work.
The TAILORx trial enrolled more than 10,000 women across multiple countries. It found that for most women with hormone receptor-positive, HER2-negative, node-negative early breast cancer and a Recurrence Score of 25 or below, hormone therapy alone worked as well as chemotherapy combined with hormone therapy. The National Institutes of Health reported that for women aged 50 or younger, some in the intermediate score range (11 to 25) got a small benefit from adding chemotherapy - so age matters alongside the score.
For many women, a low or intermediate result means they can skip chemotherapy's side effects without affecting long-term outcomes. That's useful information - but it's about chemotherapy, not surgery.
Which Factors Actually Decide Mastectomy vs Lumpectomy?
| Factor | Influences Mastectomy vs Lumpectomy? | Influences Chemotherapy Decision? |
|---|---|---|
| Tumour size relative to breast size | Yes - larger tumours or a small breast may make lumpectomy technically hard | Indirectly, as part of overall staging |
| Number and position of tumours | Yes - multiple tumours spread across the breast usually point toward mastectomy | No direct role |
| BRCA gene variant status | Yes - BRCA1 or BRCA2 variants raise the risk of a new cancer in the same or opposite breast | No direct role in chemotherapy choice |
| Lymph node involvement | Indirectly - significant lymph node involvement affects overall treatment planning | Yes - node-positive cancers carry higher systemic risk |
| Oncotype DX Recurrence Score | No - the score is not used to pick surgery type | Yes - this is the main purpose of the test |
| Patient preference and personal values | Yes - your wishes are part of the decision and you have the right to be involved | Considered alongside clinical evidence |
Sources: NICE guidance DG34; Breast Cancer Now
The table shows a clear difference. The factors that shape your surgery decision - tumour size, the number and position of tumours, your BRCA status, and your own wishes - are separate from what Oncotype DX measures. In most cases, Oncotype DX is done after the surgical plan has taken shape based on these clinical factors. It informs the chemotherapy decision after surgery, not the surgery itself.
Why Do Some Women Assume Oncotype DX Decides Their Surgery?
The confusion makes sense. When you're newly diagnosed, every test feels big. The Oncotype DX result comes back with a number, and numbers feel like facts. It's easy to think a high score means you need more aggressive surgery.
But the score measures a different kind of risk. It asks: if cancer cells break away from this tumour and travel through the bloodstream to other organs, how likely is that, and would chemotherapy help? That's a question about systemic treatment - about your blood and organs. It's not about how much breast tissue should come out.
Two kinds of recurrence matter after breast cancer surgery. Local recurrence is cancer coming back in the breast or nearby tissue. Distant recurrence is cancer appearing in another organ. Surgery and radiation stop local recurrence. Chemotherapy and hormone therapy stop distant recurrence. Oncotype DX looks at distant recurrence risk - not local recurrence risk.
Understanding this can actually be reassuring. If your Recurrence Score comes back low, it doesn't mean your surgeon was wrong to discuss mastectomy for size reasons. If your score is high, it doesn't mean mastectomy is necessary. Your surgical team will still base that recommendation on what fits your tumour and your body.
You might also find it helpful to read about what your breast cancer pathology report means for surgery, which explains how your biopsy results and biomarker findings work together for surgery planning - separate from any genomic test.
When Can a High Score Prompt a Broader Conversation About Surgery?
There's one case where a high Recurrence Score may shape surgery talks. If your score is high and your oncologist recommends chemotherapy before surgery - called neoadjuvant chemotherapy - how your tumour responds to that treatment can affect which surgery becomes possible.
Some tumours shrink a lot during neoadjuvant chemotherapy. If your tumour was too large for lumpectomy at first, a strong response to chemotherapy might make breast-saving surgery possible. In this case, your genomic profile affects the treatment order that changes your surgical options - even if the score itself wasn't the direct input into the surgery decision.
If you're in this position - high score, chemotherapy recommended before surgery, and surgical options still open - ask your team: after chemotherapy, will we check if lumpectomy is possible? That's a fair question, and the answer could give you more options.
If you want an independent view of how your Oncotype DX results fit with your surgical plan, you can ask Art of Healing Cancer to review your reports. Their team works with women deciding on breast cancer surgery, including access to robotic breast-saving techniques.
Oncotype DX and the NHS: What You Need to Know
NICE - the body that decides which tests and treatments should be available on the NHS in England - has approved Oncotype DX for women with hormone receptor-positive, HER2-negative, node-negative early breast cancer who fall into an intermediate-risk group by standard tools. In 2024, this was extended to women with one to three positive lymph nodes. The core eligibility criteria are in NICE guidance document DG34.
Three tumour profiling tests are currently approved under NICE guidance: Oncotype DX, Prosigna, and EndoPredict. Your oncologist will say which is best for you. If you meet the criteria, the test is available on the NHS free of charge.
If you're considering private care or treatment outside the UK, it's worth asking if Oncotype DX has already been ordered and whether the results can be shared with an international team. In most cases they can. Your Recurrence Score goes with you and can help any consultation regardless of where your surgery happens.
Lumpectomy vs Mastectomy: What the Evidence Shows Long-Term
A common worry among women thinking about lumpectomy is whether keeping the breast means higher risk of cancer returning. Evidence from decades of research shows that for suitable candidates, lumpectomy plus radiation produces long-term survival that matches mastectomy. This applies when tumour size and location allow clear margins, and when there are no clinical reasons - like BRCA status or multiple tumours - that make mastectomy more appropriate.
For more on how tumour grade and stage affect which surgery is right for you, see the article on how grade and stage shape your breast cancer surgery. If you want to look at local and distant recurrence rates between the two approaches, the article on recurrence risk after robotic lumpectomy vs mastectomy covers the evidence in detail.
What Oncotype DX adds is precision about distant recurrence risk specific to your tumour's biology. That precision helps your oncologist fit systemic treatment - chemotherapy, hormone therapy, or both - to your situation, rather than using the same approach for everyone at the same stage.
Questions to Ask Your Team About Oncotype DX
If Oncotype DX has been recommended - or if you're wondering if it applies to you - ask your team these questions at your next visit:
- Do I meet the NHS criteria for Oncotype DX, or would I need private care?
- How will my Recurrence Score be used with my other test results and clinical risk factors?
- If my score is high, does that change the chemotherapy plan - and does it affect the surgery recommendation?
- If chemotherapy is recommended before surgery, could my surgical options change based on how the tumour responds?
- Can I get a second opinion on how to interpret my score if I'm unsure about the recommendations?
Your team - usually a breast surgeon, an oncologist, and a specialist breast nurse - should be able to answer all of these. If any answer is unclear, you can ask for it to be explained again or request a written summary of what the score means for your case.
If you're deciding on surgery and would like to talk with a specialist team, you can send a question through BreastCancer.One. Female coordinators are available, and you can share your reports in private before committing to any plan.
When to Talk to Your Doctor
Talk to your oncologist or breast care nurse if you got an Oncotype DX result and aren't sure how it connects to your surgery decision. If you're about to choose a surgery and haven't discussed Oncotype DX with your team yet, ask whether it applies to you. If your questions haven't been fully answered, asking for a second opinion - from the NHS, privately, or from a specialist breast team elsewhere - is always an option.
This article is for general educational purposes and is not a substitute for personalized medical advice from a qualified oncologist. Always consult your oncologist or care team about your specific situation.